These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 8870441)
1. Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience. Chueh SC; Yu HJ; Chiu TY; Huang CY; Lai MK J Formos Med Assoc; 1996 Aug; 95(8):650-2. PubMed ID: 8870441 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Nickel JC; Fradet Y; Boake RC; Pommerville PJ; Perreault JP; Afridi SK; Elhilali MM CMAJ; 1996 Nov; 155(9):1251-9. PubMed ID: 8911291 [TBL] [Abstract][Full Text] [Related]
3. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Keetch DW; Andriole GL; Ratliff TL; Catalona WJ Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial. Yu HJ; Chiu TY; Lai MK J Formos Med Assoc; 1995; 94(1-2):37-41. PubMed ID: 7542109 [TBL] [Abstract][Full Text] [Related]
5. The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia. Wu TT; Lee YH; Jiaan BP; Huang JK Zhonghua Yi Xue Za Zhi (Taipei); 1995 Dec; 56(6):399-403. PubMed ID: 8851481 [TBL] [Abstract][Full Text] [Related]
6. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group. Stoner E Arch Intern Med; 1994 Jan; 154(1):83-8. PubMed ID: 7505563 [TBL] [Abstract][Full Text] [Related]
8. Finasteride in the treatment of benign prostatic hyperplasia. Ekman P; Andersen JT; Wolf H Acta Urol Belg; 1996 Mar; 64(1):IX-XII. PubMed ID: 8659328 [TBL] [Abstract][Full Text] [Related]
9. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Andersen JT; Ekman P; Wolf H; Beisland HO; Johansson JE; Kontturi M; Lehtonen T; Tveter K Urology; 1995 Nov; 46(5):631-7. PubMed ID: 7495111 [TBL] [Abstract][Full Text] [Related]
10. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J; J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299 [TBL] [Abstract][Full Text] [Related]
11. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762 [TBL] [Abstract][Full Text] [Related]
12. The effect of finasteride on prostate specific antigen: review of available data. Guess HA; Gormley GJ; Stoner E; Oesterling JE J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873 [TBL] [Abstract][Full Text] [Related]
13. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J Urology; 1997 Jul; 50(1):13-8. PubMed ID: 9218012 [TBL] [Abstract][Full Text] [Related]
14. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. Marks LS; Partin AW; Gormley GJ; Dorey FJ; Shery ED; Garris JB; Subong EN; Stoner E; deKernion JB J Urol; 1997 Jun; 157(6):2171-8. PubMed ID: 9146609 [TBL] [Abstract][Full Text] [Related]
15. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). Nickel JC; Gilling P; Tammela TL; Morrill B; Wilson TH; Rittmaster RS BJU Int; 2011 Aug; 108(3):388-94. PubMed ID: 21631695 [TBL] [Abstract][Full Text] [Related]
16. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia]. Tkachuk VN; Al'-Shukri SKh; Kornienko VI; Kuz'min IV Urol Nefrol (Mosk); 1998; (4):37-9. PubMed ID: 9727320 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Lam JS; Romas NA; Lowe FC Urology; 2003 Feb; 61(2):354-8. PubMed ID: 12597947 [TBL] [Abstract][Full Text] [Related]
18. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Stoner E Urology; 1994 Mar; 43(3):284-92; discussion 292-4. PubMed ID: 7510911 [TBL] [Abstract][Full Text] [Related]
19. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369 [TBL] [Abstract][Full Text] [Related]
20. Effects of finasteride on prostate volume and prostate-specific antigen. Chiu KY; Yong CR J Chin Med Assoc; 2004 Nov; 67(11):571-4. PubMed ID: 15720071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]